Valuation: Lupin Limited

Market Cap 1,001B 10.46B 8.96B 8.38B 7.67B 14.46B 14.62B 99.21B 38.58B 503B 39.27B 38.42B 1,664B P/E 2027 *
22.7x
P/E 2028 * 21.4x
Enterprise Value 958B 10B 8.57B 8.02B 7.33B 13.83B 13.98B 94.88B 36.89B 481B 37.55B 36.74B 1,591B EV / Sales 2027 *
3.16x
EV / Sales 2028 * 2.88x
Free-Float
52.97%
Yield 2027 *
0.58%
Yield 2028 * 0.58%
1 day-0.68%
1 week-2.25%
Current month-9.90%
1 month-9.75%
3 months-4.94%
6 months-5.12%
Current year+2.98%
1 week 2,159.4
Extreme 2159.4
2,243.05
1 month 2,159.4
Extreme 2159.4
2,475
Current year 2,072.95
Extreme 2072.95
2,530
1 year 1,881.8
Extreme 1881.8
2,530
3 years 1,076.05
Extreme 1076.05
2,530
5 years 583.05
Extreme 583.05
2,530
10 years 505
Extreme 505
2,530
Manager TitleAgeSince
Chief Executive Officer 58 2013-08-31
Director of Finance/CFO 61 2007-08-12
Compliance Officer - 2024-08-31
Director TitleAgeSince
Director/Board Member 52 2008-10-07
Director/Board Member 58 1996-12-31
Chairman 82 2017-08-10
Change 5-day change 1-year change 3-year change Capi.($)
-0.68%-2.25%+10.72%+101.85% 10.46B
-0.67%+5.39%+75.21%+127.54% 1,111B
+1.04%+4.07%+52.29%+65.39% 658B
-0.17%+5.67%+25.60%+80.40% 467B
+0.16%+2.80%+42.75%+43.13% 369B
+0.28%+1.18%+25.48%+41.60% 301B
+0.86%+3.46%+2.88%+14.58% 256B
+1.03%+5.83%+51.11%+72.96% 240B
+2.31%+3.04%-16.87%-52.21% 207B
+0.42%+5.63%+27.86%+92.24% 182B
Average +0.09%+3.74%+29.70%+58.75% 380.15B
Weighted average by Cap. -0.09%+4.66%+44.22%+73.41%

Financials

2027 *2028 *
Net sales 303B 3.16B 2.71B 2.54B 2.32B 4.38B 4.42B 30.02B 11.67B 152B 11.88B 11.62B 503B 321B 3.35B 2.87B 2.69B 2.46B 4.63B 4.68B 31.79B 12.36B 161B 12.58B 12.31B 533B
Net income 43.72B 457M 391M 366M 335M 632M 638M 4.33B 1.68B 21.95B 1.71B 1.68B 72.63B 46.71B 488M 418M 391M 358M 675M 682M 4.63B 1.8B 23.45B 1.83B 1.79B 77.6B
Net Debt -43.72B -457M -391M -366M -335M -631M -638M -4.33B -1.68B -21.95B -1.71B -1.68B -72.63B -78.59B -821M -703M -658M -602M -1.14B -1.15B -7.79B -3.03B -39.46B -3.08B -3.01B -131B
Logo Lupin Limited
Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas: - design and production of generic and brand-name formulations; - production of active pharmaceutical ingredients. At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil. Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).
Employees
26,021
Date Price Change Volume
26-08-25 2,175.00 -0.68% 190,477
26-08-24 ₹2,190.00 -0.14% 12,257
26-08-21 ₹2,193.00 -0.46% 30,973
26-08-20 ₹2,203.10 -0.76% 7,623
26-08-19 ₹2,220.00 -0.22% 10,235
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
36
Last Close Price
2,190.00INR
Average target price
2,509.89INR
Spread / Average Target
+14.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LUPIN Stock